Home » Stocks » FRLN

Freeline Therapeutics Holdings PLC (FRLN)

Stock Price: $18.20 USD 0.10 (0.55%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 632.35M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 33.23M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $18.20
Previous Close $18.10
Change ($) 0.10
Change (%) 0.55%
Day's Open 17.68
Day's Range 17.66 - 18.20
Day's Volume 2,522
52-Week Range 14.94 - 18.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-bas...

GlobeNewsWire - 1 month ago

Updated dose-ranging data demonstrate potential for full normalization of FIX activity

GlobeNewsWire - 2 months ago

LONDON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-bas...

GlobeNewsWire - 2 months ago

LONDON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-bas...

About FRLN

Freeline Therapeutics Holdings plc operates as a clinical-stage systemic adeno-associated virus (AAV)-based gene therapy company. Its advanced product candidate is FLT180a, a gene therapy product candidate that is being evaluated in a Phase 1/2 dose-finding clinical trials in adult males for the treatment of patients with moderate or severe hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to ... [Read more...]

Industry
Biotechnology
IPO Date
Aug 7, 2020
CEO
Theresa Marie Heggie
Employees
200
Stock Exchange
NASDAQ
Ticker Symbol
FRLN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for FRLN stock is "Buy." The 12-month stock price forecast is 28.75, which is an increase of 57.97% from the latest price.

Price Target
$28.75
(57.97% upside)
Analyst Consensus: Buy